Anavex Life Sciences Corp (AVXL)

[Gator328]

Well, back in January of this year Rhythm Pharma sold theirs for $100mm.

And back in 2018, Spark Therapeutics sold theirs to Jazz Pharma for $110mm.

Also in 2018, Ultragenyx sold theirs for $80mm.

I could keep on going but I think you get the idea. The value of these vouchers today isn't worth nearly what they went for half-a-decade ago, namely because the FDA has tried to streamline the approval process per President Trump's request.

The rare priority review voucher is worth more for Anavex to use to expedite its Alzheimer's pipeline, particularly if there is competition from other drug companies like SAVA...

https://pharmaphorum.com/news/spark-sells-priority-review-voucher-to-jazz/

https://www.biopharmadive.com/news/ultragenyx-prv-sale-value-regulation-fast-pass/529221/